| Literature DB >> 11148250 |
A C Kappelle1, T J Postma, M J Taphoorn, G J Groeneveld, M J van den Bent, C J van Groeningen, B A Zonnenberg, K C Sneeuw, J J Heimans.
Abstract
The authors evaluated response, time to progression (TTP), survival, prognostic factors, and toxicity in 63 patients with a recurrent glioblastoma multiforme treated with procarbazine, lomustine, and vincristine (PCV) chemotherapy. Complete and partial response was observed in two (3%) and five patients (8%). In 16 patients (25%), stable disease was observed. Median TTP and survival were 13 and 33 weeks. Age < 40 years and Karnofsky Performance Status > or = 90 were associated with longer TTP and survival. PCV treatment was generally well tolerated.Entities:
Mesh：
Substances：
Year: 2001 PMID： 11148250 DOI： 10.1212/wnl.56.1.118
Source DB: PubMed Journal: Neurology ISSN： 0028-3878 Impact factor: 9.910